NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/07/2025
Back to search
Official data from USPTO
NEXCELLA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NEXCELLA
ST13
US500000097730524Class
42, 44
Filing
97730524
Registration
7977050
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
18
Latest update
10/08/2025
Trademark type
Word
Nice classes
42, 44
Filing date
12/23/2022
Registration date
10/07/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/07/2025
Last transaction
10/08/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
11/20/2022
First use in commerce
01/01/2023
Drawing code
4
Owner type
03
Owner location
Los Angeles, CA
Examiner
SWIFT,GILBERT M
Law office
L90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
NEXCELLA, INC.
Representatives
Sheila R. Gibson AURA IP LAW
Technical classification
Nice Classes
Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
scientific research in the field of oncology; scientific research in the field of immuo-dysregulated diseases; development of pharmaceutical preparations and medicines for the treatment of cancer; development of pharmaceutical preparations and medicines for the treatment of immuno-dysregulated diseases; clinical research in the field of oncology; clinical research in the field of immuo-dysregulated diseases; research and development services in the field of anti-cancer preparations; research and development services in the field of preparations for treating immuno-dysregulated diseases; designengineeringresearchdevelopment and testing services in the field of oncology; designengineeringresearchdevelopment and testing services in the field of immuno-dysregulated diseases; providing information regarding medical research relating to oncology; providing information regarding medical research relating to immuno-dysregulated diseases
Class 44
providing medical information about the treatment of cancer; providing medical information about the treatment of immuno-dysregulated diseases; providing a website featuring healthcare and medical informationinformation about cancer and the treatment of cancer; providing a website featuring healthcare and medical informationinformation about immuno-dysregulated diseases and the treatment of immuno-dysregulated diseases
Publications
History of USPTO decisions and trademark events.
18 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
10/07/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/03/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/12/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/12/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
08/05/2025
IUAF
USE AMENDMENT FILED
08/07/2024
EISU
TEAS STATEMENT OF USE RECEIVED
08/07/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/30/2024
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
03/17/2024
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
12/01/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/07/2023
PUBO
PUBLISHED FOR OPPOSITION
11/07/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/18/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/29/2023
DOCK
ASSIGNED TO EXAMINER
09/23/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/20/2023
NWAP
NEW APPLICATION ENTERED
12/27/2022
Continuous trademark protection
Get notified about every new filing that threatens NEXCELLA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.